SOURCE: OmniComm Systems, Inc.

June 11, 2007 10:00 ET

OmniComm Systems, Inc. Wins a Phase II, Multi-Center International Clinical Trial for a Major West Coast Biopharmaceutical Company

Electronic Data Capture (EDC) Company Poised to Deliver Hosted EDC Services for the First in a Series of Clinical Trials for This Industry Leader

FT. LAUDERDALE, FL--(Marketwire - June 11, 2007) - OmniComm Systems, Inc. (OTCBB: OMCM), one of the fastest growing companies in the EDC market place, today announced that it has begun working with a multi-billion dollar West Coast global pharmaceutical company on a Phase II, multi-center study. OmniComm's subsidiary in Europe, OmniComm Europe GMBH located in Bonn, Germany will provide full ASP hosted support and services for the duration of the trial.

"The fact that this key pharmaceutical innovator has chosen OmniComm as its EDC vendor for this clinical trial is evidence that we are on the right track in our efforts to deliver superior EDC services and support to the clinical trials industry," said Stephen Johnson, Sr. VP of Business Development for OmniComm. "Our European staff stands ready to deliver first-class customer support and related trial management services for this industry leader."

The pharmaceutical company employs the most advanced scientific tools to develop therapeutics for the treatment of life-threatening diseases. Their goal is to create innovative therapeutics with enhanced delivery modes, fewer side effects and stronger efficacy. The company strives to advance the care of patients by developing medicines that make a significant difference in the treatment of life-threatening diseases.

"Our ultimate goal is to develop a long-term relationship with this visionary drug development company," said Cornelis F. Wit, CEO of OmniComm Systems, Inc. "We feel confident that the ease of use of the TrialMaster® EDC solution, coupled with the superior functionality in the product, will exceed the company's expectations for this trial and translate into a fruitful relationship between our two companies."

About OmniComm

OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm's client intuitive pricing model allows companies that range from small to mid-size to large scale institutions to safely and efficiently capitalize on their clinical research investments.

OmniComm ranked in the top 150 as one of the fastest revenue growth technology companies in North America during the last 5 years. In a market overview titled "The Promise of Next-Gen eClinical Trial Software" by Forrester Research, OmniComm was given the highest rating among its competitors for industry middleware. OmniComm Systems Inc. has corporate headquarters in Ft. Lauderdale, Florida with offices in Bonn, Germany, California, Maryland, New York, North Carolina and Texas.

Safe Harbor Disclaimer

Statements about OmniComm's future expectations, including without limitation, future revenues and earnings, plans and objectives for the future operations, future agreements, future economic performance, operations and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. OmniComm intends that such forward-looking statements be subject to the Safe Harbors created thereby. Since these statements involve risks and uncertainties, including but not limited to economic competitive, governmental, contractual and technological factors affecting OmniComm's operations, markets and profitability, actual results could differ materially and adversely from the expected results.

Contact Information

  • CONTACT:
    Lizanne Kelley
    OmniComm Systems, Inc.
    954-473-1254 Extension 283
    Email Contact